Socioeconomic Disparities Impact Immunotherapy Use in Urologic Cancers
By Lori Solomon HealthDay Reporter
FRIDAY, Sept. 6, 2024 -- Immunotherapy (IO) utilization is increasing over time, but significant socioeconomic disparities exist for patients with advanced clear cell renal cell carcinoma (ccRCC) and urothelial carcinoma of the bladder (UC), according to a study published in the November issue of Urologic Oncology: Seminars and Original Investigations.
Levi Holland, M.D., from the University of Texas Southwestern Medical Center in Dallas, and colleagues assessed socioeconomic and demographic factors associated with the receipt of IO for advanced ccRCC and UC. The analysis included patients with stage IV ccRCC (15,926 individuals) or UC (10,380 individuals) identified from the National Cancer Database.
The researchers found that 34.0 percent of patients with ccRCC and 21.5 percent with UC received IO therapy, with IO utilization increasing in each successive year. Treatment at a nonacademic facility, education level, income, and insurance were independently associated with IO utilization for both malignancies. For ccRCC, decreased IO use was seen for Black race (odds ratio, 0.77) and Hispanic race (odds ratio, 0.73). For UC, there were no independent associations noted between race and receipt of IO.
"With the rapidly changing pace of innovation in cancer therapeutics, it is important that all patients have access to novel, potentially lifesaving medications," lead author Solomon Woldu, M.D., also from UT Southwestern, said in a statement. "Our study highlights critical gaps in health care equity when it comes to treatments that have been shown effective in prolonging survival."
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted September 2024
Read this next
Immune Checkpoint Inhibitor Affordability Tied to Widening Survival Disparity
FRIDAY, July 11, 2025 -- The introduction of immune checkpoint inhibitors (ICIs) was associated with a widening survival disparity between those with private insurance and those...
Risk for Severe COVID-19 Elevated for Childhood Cancer Survivors
FRIDAY, July 11, 2025 -- Childhood cancer survivors have a lower risk for registered COVID-19 infection but a higher risk for severe COVID-19, according to a study published...
Uterine Cancer Incidence, Mortality Expected to Increase Through 2050
TUESDAY, July 8, 2025 -- Uterine cancer incidence and mortality rates are projected to increase significantly through 2050, according to a study published online July 1...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.